OVB.GB Ovoca Bio Plc

TIDMOVB

RNS Number : 9897W

Ovoca Bio PLC

30 December 2021

Ovoca Bio plc

("Ovoca" or the "Company")

Directorate Change

Ovoca Bio plc (LSE: OVB; ISE: OVXA) announces that Dr. Romulo Colindres has informed the Board of his decision to step down as a Non-Executive Director of the Company, with immediate effect, for both personal and business reasons. Dr. Colindres stated: "It has been a pleasure to be involved with the Ovoca board and team and wish them much success along the path to making orenetide available to patients".

Kirill Golovanov, CEO of Ovoca, commented: "On behalf of the Company, I would like to thank Romulo for his contribution to the board of Ovoca. We wish Romulo well in his future endeavours."

End

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com

Davy (Nominated Adviser, Euronext Growth Advisor and Broker)

John Frain / Daragh O'Reilly

Tel: +353 1 679 6363

Consilium Strategic Communications

Chris Gardner, Chris Welsh, Carina Jurs

ovocabio@consilium-comms.com

Tel: +44 (0)20 3709 5700

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD).

The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.

Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUKVRRASUUUUA

(END) Dow Jones Newswires

December 30, 2021 02:00 ET (07:00 GMT)

Ovoca Bio (AQSE:OVB.GB)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Ovoca Bio (AQSE:OVB.GB)
Historical Stock Chart
Von Jan 2024 bis Jan 2025